• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Portugal - MDR and XDR Tuberculosis steadily increasing

Gert van der Hoek

In Memoriam - Editor, Senior Moderator
Clin Microbiol Infect. 2010 Aug 20.

Tuberculosis Drug-Resistance in Lisbon, Portugal: a Six-Year Overview.


ABSTRACT Multidrug-resistance and extensive drug-resistance pose a serious threat to tuberculosis management in Portugal. The country has high TB incidence rates in comparison with the other European Union countries, with Lisbon Health Region being one of the most affected regions.

In the present study we have analyzed a convenience sample of 3 025 Mycobacterium tuberculosis clinical isolates, recovered over a six-year period (2001-2006) in Lisbon Health Region, regarding drug-resistance both to first-line and second-line drugs.

Moreover, one hundred of these isolates were also genotyped by 12-loci Mycobacterial Interspersed Repetitive Unit - Variable Number of Tandem Repeats (MIRU-VNTR) analysis.

We have compared each year and observed the existence of 22 different resistance profiles with MDR-TB rates ranging between 9.9-15.2% and XDR-TB rates, relative to the number of MDR-TB isolates, between 44.3-66.1% (excluding one year here considered as an outlier).

A steady increase in the fraction of MDR-TB isolates resistant to all first-line drugs was also noticed. The genotyping analysis of MDR-TB isolates revealed six clusters, of which three (Lisboa3, Lisboa 4 and Q1) were related with XDR-TB.

Our results show that active transmission of MDR- and XDR-TB is taking place and that the high prevalence of observed XDR-TB is due to the continued transmission of particular genetic clusters.

An early detection of resistant cases would greatly benefit from the enforcement in case detection and implementation of genotyping in diagnostic routines.

http://www.ncbi.nlm.nih.gov/pubmed/20731680
 
Back
Top Bottom